Neurologic clinical trial - Biogen ATLAS 233AS303

Neurologic

Status:

Open and enrolling

A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Drug

BIIB067

Phase

Phase 3

Condition

Amyotrophic Lateral Sclerosis (ALS)

Keywords

SOD1 mutation in Amyotrophic Lateral Sclerosis (ALS) | Biogen